Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Top Cited Papers
- 8 November 2010
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet Neurology
- Vol. 9 (12), 1157-1163
- https://doi.org/10.1016/s1474-4422(10)70274-x
Abstract
No abstract availableFunding Information
- Boehringer Ingelheim
This publication has 13 references indexed in Scilit:
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAmerican Heart Journal, 2009
- New oral anticoagulants in atrial fibrillationEuropean Heart Journal, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial FibrillationStroke, 2007
- Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial FibrillationStroke, 1997
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991